Literature DB >> 23281417

From an ACE polymorphism to genome-wide searches for eQTL.

Florent Soubrier1.   

Abstract

Angiotensin I-converting enzyme (ACE, or DCP1) is a zinc metallopeptidase that converts angiotensin I into the vasoactive and aldosterone-stimulating peptide angiotensin II and cleaves bradykinin into inactive peptides. Plasma ACE measurement is widely used for the diagnosis of sarcoidosis. While enzyme concentrations are highly stable in an individual, there is a high level of interindividual variability. In 1990, we identified an insertion/deletion polymorphism in ACE that functions as a quantitative trait locus (QTL), accounting for half of the interindividual variability. Since then, technological advances have allowed for the elucidation of expression QTLs (eQTL). Such studies are allowing researchers to determine how underlying genetic predisposition contributes to human disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23281417      PMCID: PMC3533308          DOI: 10.1172/JCI66618

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

1.  Angiotensin-1-converting enzyme (ACE) plasma concentration is influenced by multiple ACE-linked quantitative trait nucleotides.

Authors:  Roger Cox; Nourdine Bouzekri; Sabrina Martin; Lorraine Southam; Alison Hugill; Mahamadee Golamaully; Richard Cooper; Adebowale Adeyemo; Florent Soubrier; Ryk Ward; G Mark Lathrop; Fumihiko Matsuda; Martin Farrall
Journal:  Hum Mol Genet       Date:  2002-11-01       Impact factor: 6.150

Review 2.  Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists.

Authors:  Michel Azizi; Joël Ménard
Journal:  Circulation       Date:  2004-06-01       Impact factor: 29.690

Review 3.  Angiotensin-converting enzyme: new concepts concerning its biological role.

Authors:  M R Ehlers; J F Riordan
Journal:  Biochemistry       Date:  1989-06-27       Impact factor: 3.162

4.  Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse.

Authors:  W Huang; Y Gallois; N Bouby; P Bruneval; D Heudes; M F Belair; J H Krege; P Meneton; M Marre; O Smithies; F Alhenc-Gelas
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

5.  Familial resemblance of plasma angiotensin-converting enzyme level: the Nancy Study.

Authors:  F Cambien; F Alhenc-Gelas; B Herbeth; J L Andre; R Rakotovao; M F Gonzales; J Allegrini; C Bloch
Journal:  Am J Hum Genet       Date:  1988-11       Impact factor: 11.025

6.  Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning.

Authors:  F Soubrier; F Alhenc-Gelas; C Hubert; J Allegrini; M John; G Tregear; P Corvol
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

7.  Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction.

Authors:  F Cambien; O Poirier; L Lecerf; A Evans; J P Cambou; D Arveiler; G Luc; J M Bard; L Bara; S Ricard
Journal:  Nature       Date:  1992-10-15       Impact factor: 49.962

8.  Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes.

Authors:  O Costerousse; J Allegrini; M Lopez; F Alhenc-Gelas
Journal:  Biochem J       Date:  1993-02-15       Impact factor: 3.857

9.  An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels.

Authors:  B Rigat; C Hubert; F Alhenc-Gelas; F Cambien; P Corvol; F Soubrier
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

10.  Angiotensin-converting enzyme insertion/deletion polymorphism contributes to ischemic stroke risk: a meta-analysis of 50 case-control studies.

Authors:  Zhizhong Zhang; Gelin Xu; Dezhi Liu; Xinying Fan; Wusheng Zhu; Xinfeng Liu
Journal:  PLoS One       Date:  2012-10-01       Impact factor: 3.240

View more
  5 in total

1.  Angiotensin-converting enzyme gene insertion/deletion polymorphism in Saudi patients with rheumatic heart disease.

Authors:  Khalid M Al-Harbi; Ibrahim S Almuzaini; Mohamed M Morsy; Nada A Abdelaziz; Alia M Al-Balawi; Atiyeh M Abdallah
Journal:  Saudi Med J       Date:  2015-02       Impact factor: 1.484

2.  High-Saturated-Fat Diet Increases Circulating Angiotensin-Converting Enzyme, Which Is Enhanced by the rs4343 Polymorphism Defining Persons at Risk of Nutrient-Dependent Increases of Blood Pressure.

Authors:  Rita Schüler; Martin A Osterhoff; Turid Frahnow; Anne-Cathrin Seltmann; Andreas Busjahn; Stefan Kabisch; Li Xu; Alexander S Mosig; Joachim Spranger; Matthias Möhlig; Silke Hornemann; Michael Kruse; Andreas F H Pfeiffer
Journal:  J Am Heart Assoc       Date:  2017-01-17       Impact factor: 5.501

3.  Investigation of angiotensin-I-converting enzyme (ACE) inhibitory tri-peptides: a combination of 3D-QSAR and molecular docking simulations.

Authors:  Fangfang Wang; Bo Zhou
Journal:  RSC Adv       Date:  2020-09-30       Impact factor: 4.036

4.  The Effect of Angiotensin Converting Enzyme (ACE) I/D Polymorphism on Atherosclerotic Cardiovascular Disease and Cardiovascular Mortality Risk in Non-Hemodialyzed Chronic Kidney Disease: The Mediating Role of Plasma ACE Level.

Authors:  Hendri Susilo; Budi Susetyo Pikir; Mochammad Thaha; Mochamad Yusuf Alsagaff; Satriyo Dwi Suryantoro; Citrawati Dyah Kencono Wungu; Ifan Ali Wafa; Cennikon Pakpahan; Delvac Oceandy
Journal:  Genes (Basel)       Date:  2022-06-23       Impact factor: 4.141

5.  Absence of cell surface expression of human ACE leads to perinatal death.

Authors:  Annie Michaud; K Ravi Acharya; Geoffrey Masuyer; Nicole Quenech'du; Olivier Gribouval; Vincent Morinière; Marie-Claire Gubler; Pierre Corvol
Journal:  Hum Mol Genet       Date:  2013-10-24       Impact factor: 6.150

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.